A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.

PubMed Daily Triage — 2026-08-15

Run ID: 2026-08-15-attempt1-20260815T090000Z | Attempt: 1 of 3
Date window: 2026-08-14 00:00 UTC → 2026-08-15 23:59 UTC
Model: anthropic/claude-sonnet-4-6 | Generated: 2026-08-15T09:10Z
Articles: 29 total (7 HIGH · 22 STANDARD) across 9 active topics

Summary

Topic	Candidates Reviewed	HIGH	STANDARD
Hematologic malignancies	15	2	3
CBC / ML hematology	0	0	0
Early cancer detection	11	0	5
AI/ML diagnostics	15	1	1
Precision oncology	15	1	2
Novel therapeutics	15	0	0 ⚠️ partial
Cardiovascular-metabolic	15	0	6
Aging & longevity	15	0	3
Rare diseases	7	3	1
Sentinel (cross-topic)	10	0	0

Coverage flags: T2 (CBC/ML) returned 0 results in both primary and fallback searches; T6 (novel therapeutics) esummary batches were truncated — 0 T6-specific articles fully confirmed.

⬆️ HIGH Priority (score 8/10)

1. Prostate MRI: AI + Human Reading + PSA Density — Multi-reader Validation

Combining AI classification with expert radiologist reading and PSA density improved prostate MRI focal lesion characterization in a multi-reader design, directly addressing inter-reader variability in clinical mpMRI interpretation.

Authors: Mondon P, Abichou-Klich A, Souchon R, L'Huillier R, Colombel M, Ruffion A, Crouzet S, Rabilloud M, Rouvière O
DOI: 10.1016/j.diii.2026.08.004

2. SF3b Complex in Cancer — Structural Basis, Mechanisms & Therapeutic Opportunities

SF3B1 mutations (~25% of MDS, common in CLL/AML) drive aberrant splicing of tumor suppressors; emerging small-molecule SF3b inhibitors (H3B-8800) show synthetic lethality in SF3B1-mutant hematologic cancers.

Authors: Li S, Shang L, Yang J, Huang Y, Liu W, Xie Y, Dong Z, Jiang Y, Liu K
DOI: 10.1182/bloodadvances.2026020106

3. ARID1B Mutations → VISTA Upregulation → Immune Evasion in AML

ARID1B loss-of-function upregulates the immune checkpoint VISTA on AML blasts; VISTA blockade restores T-cell antitumor immunity in ARID1B-mutant models — a novel chromatin-to-immunocheckpoint axis.

Authors: Mao W, Cui J, Su H, Yang Y, Zhou T, Li F, Jiang S, Han Y, Yu K, Huang K, Zhang S
DOI: 10.1016/j.intimp.2026.117270

4. SIRI Biomarker Predicts Outcomes & Chemo Benefit in Metastatic Pancreatic Cancer (PANTHEIA-SEOM)

SIRI (monocyte × neutrophil / lymphocyte, derivable from routine CBC) independently predicts OS and differential chemotherapy benefit in metastatic pancreatic cancer across a large Spanish multicenter cohort — immediately implementable for risk stratification.

Authors: Carmona-Bayonas A, Mariño Méndez A, Vicente-Conesa MÁ, Jimenez-Fonseca P, de Toro Carmena M, Guillen-Ponce C, Lamarca A, Benavente M, Gallego J + 12 others
DOI: 10.1016/j.pan.2026.08.008

5. GNE-Related Thrombocytopenia — Pathogenesis, Diagnosis & Treatment (Case Series)

GNE mutations drive platelet-specific sialyltransferase dysfunction distinct from GNE myopathy; this JTH case series defines the pathogenic mechanism and clinical management approach for this ultra-rare inherited platelet disorder.

Authors: Barozzi S, Di Buduo CA, Zampieri S, Isidori F, Frisari S, Lassandro G, Lunghi M, Martinotti A, Bozzi V, Mina T, Cesaro S, Pippucci T, Giordano P, Balduini A, Pecci A
DOI: 10.1016/j.jtha.2026.08.004

6. Efgartigimod Real-World MG Outcomes — Large Patient Support Database

PMID: 42598382 | Journal: Frontiers in Neurology | Date: 2026-07-30
Topic: Rare diseases | Score: 8 | Access: 🔓 open (PMC13470747)
Study design: Real-world retrospective cohort (large patient support program database) | Species/model: human

Large real-world database confirms efgartigimod MG-ADL improvements in clinical practice with dosing pattern heterogeneity from trial protocols; validates approved FcRn antagonist therapy beyond trial conditions.

Authors: Narayanaswami P, Smith AG, Bhavaraju-Sanka R, Qi C, Jefferson M, Aldridge J, Heerlein K, Gelinas D, Dhingra M, Menon RR, Sato M, Wolfe GI
DOI: 10.3389/fneur.2026.1881758

7. GLP-1 Receptor Agonists in Wolfram Syndrome — First Therapeutic Evaluation

GLP-1 RAs show metabolic and potential neuroprotective benefit in Wolfram syndrome (WFS1/CISD2 mutations), representing the first evaluation of disease-modifying pharmacotherapy in this uniformly fatal rare disorder. Urano lab (WS registry leaders, Washington University).

Authors: Lee LA, Tang AF, Asako AE, Ning SF, Reed HA, Duncan E, Lugar HM, Hoekel J, Marshall BA, Hershey T, Urano F
DOI: 10.3389/fendo.2026.1847818

📋 STANDARD Priority (score 5–7)

Hematologic Malignancies

42601332 (score 7) — Am J Hematol — US Consensus: Asparaginase in ALL Multidisciplinary Care. Ali A et al. Expert consensus panel recommendations for asparaginase toxicity management and dose optimization. DOI: 10.1002/ajh.70458

42601271 (score 7) — Clin Lymphoma Myeloma Leuk — SOHO: Individualizing Treatment in Myelofibrosis. Hunter AM, Bose P. State of the Art review covering JAK inhibitor selection, dynamic risk tools (MIPSS70+), and emerging combinations for MF. DOI: 10.1016/j.clml.2026.07.010

42600468 (score 6) — Bioorganic Chemistry — Novel Quinazoline ATR Inhibitor for AML. Li X et al. New quinazoline scaffold ATR kinase inhibitors with anti-AML activity in cell lines; novel chemotype for DDR targeting. DOI: 10.1016/j.bioorg.2026.110363

42601310 (score 6) — Seminars in Nuclear Medicine — PET/CT in Paediatric Lymphoma: Current Role and Advances. Ayeni A et al. Deauville scoring, response-adapted therapy, and AI-assisted quantification in paediatric lymphoma imaging. DOI: 10.1053/j.semnuclmed.2026.07.013

Early Cancer Detection

42601275 (score 7) — Journal of Hepatology — Future of Blood-Based Biomarkers in Liver Cancer. Singal AG, Saborowski A, Parikh ND, Banales JM. Comprehensive J Hepatol review covering AFP, AFP-L3, DCP, ctDNA, and multi-analyte panels (GALAD) for HCC surveillance. DOI: 10.1016/j.jhep.2026.03.040

42600715 (score 7) — Cellular Signalling — TAGLN2-CSNK1E-YAP Axis in Mesenchymal CTC Metastasis in HCC. Luo L et al. TAGLN2 drives CTC mesenchymal transition and metabolic remodeling via YAP in liver cancer; novel CTC driver. DOI: 10.1016/j.cellsig.2026.112825

42598790 (score 6) — Stem Cells and Development — Clonal Ecology Framework for Lymph Node Metastasis Prediction. Zhong KN et al. Polyclonal-to-monoclonal evolutionary transitions as a missing dimension in LN metastasis risk stratification. DOI: 10.1177/15473287261475554

42598003 (score 6) — Oncology Letters — KRAS Mosaicism as Alectinib Resistance Detected by Serial ctDNA. Simon A et al. (🔓 PMC13470051). Case report demonstrating serial ctDNA monitoring detects polyclonal KRAS resistance before radiographic progression in ALK+ NSCLC. DOI: 10.3892/ol.2026.15803

42600507 (score 5) — European Journal of Cancer — CSF ctDNA Monitoring in EGFR-RAD51 Fusion NSCLC with Leptomeningeal Metastasis. Zhang C et al. Serial CSF ctDNA biomarker for CNS disease monitoring in rare fusion-driven lung cancer. DOI: 10.1016/j.ejca.2026.116986

Precision Oncology

42601252 (score 7) — Trends in Genetics — Spatial Transcriptomics Methods for Cell-Cell Communication Analysis. Fischer Z et al. Categorization of spatial transcriptomics approaches (ligand-receptor, co-localization, cell-contact) for TME research. DOI: 10.1016/j.tig.2026.07.004

42601228 (score 6) — J Gastroenterology and Hepatology — Malaysian Consensus on HCC Prevention and Early Detection. Lau SY et al. Updated surveillance consensus incorporating GALAD score and AFP-L3 for HBV-endemic HCC prevention. DOI: 10.1111/jgh.70643

Cardiovascular-Metabolic

42600933 (score 7) — Canadian Journal of Diabetes — Prediabetes Reversion to Normoglycemia Reduces CVD and Mortality: Meta-Analysis. Eisa N, Barood O. Systematic review and meta-analysis quantifying cardiovascular and mortality benefit of normoglycemia reversion. DOI: 10.1016/j.jcjd.2026.08.003

42600923 (score 7) — Contemporary Clinical Trials — TAB Trial: Tirzepatide + Buprenorphine for Opioid Use Disorder. Winhusen TJ et al. RCT design testing tirzepatide augmentation of buprenorphine for OUD, extending GLP-1/GIP pharmacology to addiction medicine. DOI: 10.1016/j.cct.2026.108437

42600722 (score 7) — American Journal of Cardiology — CV Risk Equations Underperform in MASLD Patients. Tioh JK et al. Standard Framingham/ASCVD equations systematically underestimate CV mortality risk in MASLD, requiring MASLD-specific risk tools. DOI: 10.1016/j.amjcard.2026.08.006

42600634 (score 7) — Hormone and Metabolic Research — GLP-1 RAs and Pancreatitis/Pancreatic Cancer: Meta-Analysis. Zhong X et al. Pooled analysis does not confirm excess pancreatitis or pancreatic cancer risk from GLP-1 RA use, providing prescribing reassurance. DOI: 10.1055/a-2923-3830

42601001 (score 6) — European Journal of Pharmacology — SGLT2 Inhibition Attenuates Diabetic Lens Dysfunction via AGE-RAGE-IGFBP2-FBN1. Yeh TC et al. Novel non-cardiac SGLT2i mechanism: attenuation of diabetic cataractogenesis in mouse model. DOI: 10.1016/j.ejphar.2026.179249

42600906 (score 6) — American Heart Journal — HEPA Filtration RCT for Cardiometabolic Risk in Prediabetes. Wittkopp S et al. Double-blind sham-controlled RCT protocol testing indoor air filtration for insulin resistance improvement in NYC prediabetic adults. DOI: 10.1016/j.ahj.2026.107573

Aging & Longevity

42598190 (score 7) — Frontiers in Public Health — WHO ICOPE Step 1 Screening Tool Validation in Korean Older Adults. Chang H et al. (🔓 PMC13471507). Cross-sectional validation of WHO's integrated care screening tool for intrinsic capacity decline; population-specific calibration needed. DOI: 10.3389/fpubh.2026.1897282

42598090 (score 7) — Frontiers in Public Health — Annual Anthropometric Changes Predict Mortality in Older US Adults: 14-Year Longitudinal. Xu F et al. (🔓 PMC13471147). Progressive weight loss trajectory predicts mortality better than static BMI in older adults; challenges weight-centric aging risk frameworks. DOI: 10.3389/fpubh.2026.1894939

42601104 (score 6) — BMJ Open — Socioeconomic Gradients in Multimorbidity and Care Expenditure in Adults 65+ (Stockholm). Doheny M et al. Population-based Swedish registry study showing steep SES gradients in multimorbidity and healthcare expenditure in older adults. DOI: 10.1136/bmjopen-2025-106179

42599550 (score 5) — Journal of Physiology and Biochemistry — Astrocytes in Parkinson's Disease: Bidirectional Neuroprotection and Pathogenesis. Li Y et al. Review covering astrocyte dual roles in PD neuroprotection vs. neuroinflammation; astrocyte-targeted therapies emerging. DOI: 10.1007/s13105-026-01218-7

Rare Diseases

42600418 (score 6) — Molecular Genetics and Metabolism — Beta-Mannosidosis: Phenotypic Variability in 6 New Patients. Olivas M et al. Case series expanding the beta-mannosidosis (MANBA deficiency) phenotypic spectrum from severe ID to mild cognitive impairment; <50 total reported cases. DOI: 10.1016/j.ymgme.2026.110230

Coverage Notes

T2 (CBC/ML hematology): Zero results from primary and fallback searches on 2026-08-14/15. No CBC+ML hematology articles indexed in this window. This topic may have a longer publication lag.
T6 (Novel therapeutics): 15 candidates identified by esearch, but esummary API responses were truncated for all T6-specific batches. Zero T6-specific articles received with confirmed full metadata. T1 articles (ARID1B/VISTA AML, SF3b) have T6 relevance and are cross-listed.
Sentinel: Cross-topic sweep covered; three sentinel-matching STANDARD articles (prediabetes meta-analysis, HEPA filtration RCT, WHO ICOPE validation) are already scored under their primary topics.
Open-access articles: 42598382, 42597412, 42598190, 42598090, 42598003 have PMC full text available.

Generated by Friday (OpenClaw) · PubMed triage pipeline v1.3 · Attempt 1/3

Daily digest